ReviewAllergy2018
AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer.
Review in Allergy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
- Chronic Urticaria and Malignancy: A Review Uncovering the Common Links.Biomedicines · 2026Review
- Article
- Extracellular vesicles for targeted drug delivery: advances in surface modification strategies and therapeutic applications.Journal of translational medicine · 2025Review
- Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction.Nature communications · 2025Article
- Does Asthma Affect the Risk of Developing Breast Cancer?Cancer medicine · 2025Article
- Peripheral Inflammation Featuring Eosinophilia or Neutrophilia Is Associated with the Survival and Infiltration of Eosinophils within the Tumor among Various Histological Subgroups of Patients with NSCLC.International journal of molecular sciences · 2024Article
- Allergies and risk of head and neck cancer: a case-control study.Scientific reports · 2024Article
- Loratidine is associated with improved prognosis and exerts antineoplastic effects via apoptotic and pyroptotic crosstalk in lung cancer.Journal of experimental & clinical cancer research : CR · 2024Article
- Metabolic Reprograming of Macrophages: A New Direction in Traditional Chinese Medicine for Treating Liver Failure.Journal of immunology research · 2024Review
- Elevated IgE Levels-An Allergy or an Underlying Inborn Error of Immunity in Children with Recurrent Infections?Antibodies (Basel, Switzerland) · 2023Article
- Association between C-reactive protein-albumin-lymphocyte (CALLY) index and overall survival in patients with colorectal cancer: From the investigation on nutrition status and clinical outcome of common cancers study.Frontiers in immunology · 2023Article
- BCSCdb: a database of biomarkers of cancer stem cells.Database : the journal of biological databases and curation · 2022Article
- AllergoOncology: Role of immune cells and immune proteins.Clinical and translational allergy · 2022Review
- Review
- Comorbidities of Chronic Urticaria: A glimpse into a complex relationship.Frontiers in allergy · 2022Review
- Recent insights in the role of biomarkers in severe asthma management.Frontiers in medicine · 2022Review
- Clinical and immunological allergy assessment in cancer patients.Scientific reports · 2021Article
- Mast Cells and Skin and Breast Cancers: A Complicated and Microenvironment-Dependent Role.Cells · 2021Review
- The other side of the coin: IgE deficiency, a susceptibility factor for malignancy occurrence.The World Allergy Organization journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.